Boan Biotech (06955.HK): BA2201 (TL1A/IL-23) approved in China to initiate clinical trials, intended for the treatment of inflammatory bowel disease

Zhitong Finance APP News, Boan Biotech (06955.HK) announced that the company's independently developed Class 1 innovative drug BA2201 has been approved by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to conduct clinical trials. The investigational drug is a long-acting bispecific antibody targeting TL1A and IL-23 (p19), intended for the treatment of inflammatory bowel disease ("IBD") and other autoimmune diseases.